Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

PHASE2CompletedINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

April 15, 2020

Study Completion Date

April 15, 2020

Conditions
Dementia With Lewy Bodies
Interventions
DRUG

Irsenontrine

Oral hypromellose capsules.

DRUG

Placebo

Oral hypromellose capsules.

Trial Locations (74)

10032

Columbia University, New York

12203

Eisai Trial Site #3, Berlin

12208

Neurological Associates of Albany, PC, Albany

13385

University Hospital de la Timone, Marseille

22903

University of Virginia Adult Neurology, Charlottesville

26655

Eisai Trial Site #2, Westerstede

27103

PMG Research of Winston-Salem, LLC, Winston-Salem

28007

Hospital General Universitario Gregorio Maranon, Madrid

28222

Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda

32162

Compass Research-Bioclinica, The Villages

32174

Neurology Associates of Ormond Beach, Ormond Beach

32502

Anchor Neuroscience, Pensacola

32806

Compass Research-Bioclinica, Orlando

33137

Miami Jewish Health-Clinical Research, Miami

33155

Elias Research Associates (Allied Biomedical Research Institute), Miami

33175

Pharmax Research of South Florida; Elias Research Associates, Miami

33410

Advanced Research Consultants, Inc., Palm Beach Gardens

34128

Eisai Trial Site #1, Kassel

35128

Clinica Neurologica Azienda Ospedaliera di Padova, Padua

37920

New Orleans Center for Clinical Research, Knoxville

40504

University of Kentucky, Dept of Neurology Sanders Brown Center on Aging, Lexington

44107

Cleveland Clinic, Lou Ruvo Center for Brain Health at Lakewood Hospital, Lakewood

46202

Indiana University, Dept of Neurology, Indianapolis

48106

University of Michigan, Ann Arbor

54500

CHRU Nancy- CMRR de lorraine Hôpital de Brabois-Service de Gériatrie, Vandœuvre-lès-Nancy

59037

Centre Memoire du CHRU de Lille, Lille

66100

Universita Chieti, CeSI Met, Chieti

67000

Centre d'Investigation Clinique (CIC) Hopitaux universitaires Strasbourg HOPITAL DE HAUTEPIERRE - BATIMENT AX5, Strasbourg

69100

Centre de Recherche Clinique - Viellissement-Cerveau-Fragilite (CRC-VCF), Hopital des Charpennes, Lyon

69677

Hopital Neurologique de Lyon, Lyon

85351

Banner Sun Health Research Institute, Sun City

92117

Paradigm Clinical Research Centers, Inc, San Diego

92705

Syrentis Clinical Research, Santa Ana

92708

Parkinsons and Movement Disorders Institute, Fountain Valley

92805

Advanced Research Center Inc, Anaheim

97210

Summit Research Network (Oregon) Inc., Portland

06905

New England Institute for Clinical Research, Stamford

75231-4350

Kerwin Research Center, LLC, Dallas

263-0043

Eisai Trial Site #20, Chiba

814-0180

Eisai Trial Site #17, Fukuoka

375-0017

Eisai Trial Site #8, Fujioka-shi

371-8511

Eisai Trial Site #12, Maebashi

728-0013

Eisai Trial Site #14, Miyoshi-shi

739-0651

Eisai Trial Site #4, Otake-shi

670-0981

Eisai Trial Site #2, Himeji-shi

225-0013

Eisai Trial Site #23, Yokohama

860-8556

Eisai Trial Site #11, Kumamoto

851-2103

Eisai Trial Site #5, Nishisonogigun

940-2302

Eisai Trial Site #9, Nagaoka-shi

710-0813

Eisai Trial Site #3, Kurashiki-shi

556-0017

Eisai Trial Site #1, Naniwa-ku

590-0018

Eisai Trial Site #16, Sakai-ku, Sakai-shi

565-0871

Eisai Trial Site #24, Suita-shi

565-0874

Eisai Trial Site #13, Suita-shi

842-0192

Eisai Trial Site #6, Kanzaki-gun

113-0034

Eisai Trial Site #10, Bunkyo-ku

181-0013

Eisai Trial Site #22, Mitaka-shi

158-0098

Eisai Trial Site #18, Setagaya-Ku

742-1352

Eisai Trial Site #19, Yanai-shi

732-0066

Eisai Trial Site #25, Hiroshima

550-0012

Eisai Trial Site #21, Osaka

08221

Hospital Mutua de Terrassa, Terrassa

08006

Institut Internacional de Neurociències Aplicades, Barcelona

08228

Fundacio ACE, Barcelona

08235

Hospital Universitari Vall d'Hebron, Barcelona

TN6 1HB

Dementia Research Unit, Crowborough

S030 3JB

Memory Assessment and Research Centre, Moorgreen Hospital, Southampton

DD1 9SY

Clinical Research Centre (CRC), Dundee

G51 4TF

Queen Elizabeth University Hospital, Glasgow

TW7 6FY

West London Mental Health Trust, Isleworth

SE5 8AF

Kings College, London

W1G 9JF

Cognition Health, London

M25 3BL

Manchester Mental Health and Social Care Trust, Manchester

NE45PL

Newcastle General Hospital, Newcastle

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT03467152 - Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies | Biotech Hunter | Biotech Hunter